Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTT-3: Interferon beta-1a plus Remdesivir for COVID-19
NCT04492475Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Cytokines & Interferons
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Remdesivir + Interferon beta-1a with Remdesivir + Placebo (2 arms). Primary endpoint: Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 at Day 29. Started Aug 2020; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04492475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492475.